N-[(2S,3R,4R,5R,6R)-2-(benzyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
Structure Info
- Chemspace ID
- CSSS00020661186 (In-Stock Screening Compounds)
- MFCD
- MFCD00057920
- IUPAC Name
- N-[(2S,3R,4R,5R,6R)-2-(benzyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
- Mol formula
- C15H21NO6
- Mol weight
- 311 Da
- Catalog Number(s)
- 31747, 111777, 3554-93-6, 8397AJ, A119002827, A600947, AA00BY6U, ACM3554936, ACWONP976, AF57426, AG00BY9M, AG223994, AGN-PC-0RB3BB, AKOS027382193, AR00BYYM, B212520, BBV-78308116, BD116251, BUP08430, CD11136716, CSC020661186, EC00C0FE, F866487, F87889, FCH3957173, HY-129389, IN1405, M26345, MB04616, MS-24534, ST00BZQE, T12282, TX00BZFA, Y1251287, Y6102279, ZXC187255
- Copy structure to query editor
- SMILES
- INCHI
- INCHI key
- MOL
Properties
- LogP
- -0.85
- Heavy atoms count
- 22
- Rotatable bond count
- 5
- Number of rings
- 2
- Carbon bond saturation, Fsp3
- 0.533
- Polar surface area (Å)
- 108
- Hydrogen bond acceptors count
- 6
- Hydrogen bond donors count
- 4
![Chemical structure of N-[(2S,3R,4R,5R,6R)-2-(benzyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide (C15H21NO6) - CSSS00020661186](/st/structure/200/82b6fb5344487faf027813487365e1dc/CC%2528%253DO%2529N%255BC%2540%2540H%255D1%255BC%2540%2540H%255D%2528O%2529%255BC%2540%2540H%255D%2528O%2529%255BC%2540%2540H%255D%2528CO%2529O%255BC%2540%2540H%255D1OCC1%253DCC%253DCC%253DC1.png "C15H21NO6")
- Zoom the structure
- CSSS00020661186
Items Overall 32 items from 6 suppliers
| Supplier | Lead time | Ships from | Purity | Pack | Price, $ | Qty |
|---|---|---|---|---|---|---|
| MedChemExpress | 10 days | United States To: | 99 | 5 mg | 50.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 25 mg | 160.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 50 mg | 250.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 100 mg | 400.00 | |
| MedChemExpress | 10 days | United States To: | 99 | 1 ml | 55.00 | |
Description: Names: Benzyl-α-GalNAc; Product Description: Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation; Target: Glycosyltransferase; CAS: 3554-93-6 | ||||||
| MedChemExpress EU | 10 days | Sweden To: | 99 | 5 mg | 50.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 25 mg | 160.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 50 mg | 250.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 100 mg | 400.00 | |
| MedChemExpress EU | 10 days | Sweden To: | 99 | 1 ml | 55.00 | |
Description: Names: Benzyl-α-GalNAc; Product Description: Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation; Target: Glycosyltransferase; CAS: 3554-93-6 | ||||||
| Cayman Chemical Company, Inc | 10 days | United States To: | 90 | 25 mg | 56.32 | |
| Cayman Chemical Company, Inc | 10 days | United States To: | 90 | 50 mg | 101.20 | |
| Cayman Chemical Company, Inc | 10 days | United States To: | 90 | 100 mg | 157.52 | |
| Cayman Chemical Company, Inc | 10 days | United States To: | 90 | 250 mg | 365.20 | |
Description: CAS: 3554-93-6 | ||||||
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 5 mg | 40.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 10 mg | 64.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 25 mg | 129.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 50 mg | 198.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 100 mg | 328.00 | |
| Targetmol Chemicals Inc | 30 days | United States To: | 99 | 200 mg | 492.00 | |
Description: Benzyl-α-GalNAc (O-glycosylation-IN-1) is an effective inhibitor of O-glycosylation used to reduce the levels of mucin on the cell surface; it can inhibit the synthesis of O-glycosylated mucin in a human pancreatic cancer cell model. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, making it suitable for studies on liver fibrosis. Benzyl-α-GalNAc can be used in research on glycobiology, tumor metastasis, liver fibrosis, and chemotherapeutic sensitization.; CAS: 3554-93-6 | ||||||
| TargetMol CN | 30 days | China To: | 99 | 5 mg | 40.00 | |
| TargetMol CN | 30 days | China To: | 99 | 10 mg | 64.00 | |
| TargetMol CN | 30 days | China To: | 99 | 25 mg | 129.00 | |
| TargetMol CN | 30 days | China To: | 99 | 50 mg | 198.00 | |
| TargetMol CN | 30 days | China To: | 99 | 100 mg | 328.00 | |
| TargetMol CN | 30 days | China To: | 99 | 200 mg | 492.00 | |
Description: Benzyl-α-GalNAc (O-glycosylation-IN-1) is an effective inhibitor of O-glycosylation used to reduce the levels of mucin on the cell surface; it can inhibit the synthesis of O-glycosylated mucin in a human pancreatic cancer cell model. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, making it suitable for studies on liver fibrosis. Benzyl-α-GalNAc can be used in research on glycobiology, tumor metastasis, liver fibrosis, and chemotherapeutic sensitization.; CAS: 3554-93-6 | ||||||
| TargetMol EU | 30 days | Netherlands To: | 99 | 5 mg | 40.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 10 mg | 64.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 25 mg | 129.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 50 mg | 198.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 100 mg | 328.00 | |
| TargetMol EU | 30 days | Netherlands To: | 99 | 200 mg | 492.00 | |
Description: Benzyl-α-GalNAc (O-glycosylation-IN-1) is an effective inhibitor of O-glycosylation used to reduce the levels of mucin on the cell surface; it can inhibit the synthesis of O-glycosylated mucin in a human pancreatic cancer cell model. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, making it suitable for studies on liver fibrosis. Benzyl-α-GalNAc can be used in research on glycobiology, tumor metastasis, liver fibrosis, and chemotherapeutic sensitization.; CAS: 3554-93-6 | ||||||
For a custom pack size or bulk
please drop us a line:Enquire
please drop us a line:Enquire